These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18066142)

  • 21. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An innovative model for regulating supplement products: natural health products in Canada.
    Nestmann ER; Harwood M; Martyres S
    Toxicology; 2006 Apr; 221(1):50-8. PubMed ID: 16472903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 24. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States.
    Bhasale AL; Sarpatwari A; De Bruin ML; Lexchin J; Lopert R; Bahri P; Mintzes BJ
    Clin Pharmacol Ther; 2021 Jun; 109(6):1424-1442. PubMed ID: 32767557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
    Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
    Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 29. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural health product labels: is more information always better?
    Boon HS; Kachan N
    Patient Educ Couns; 2007 Oct; 68(2):193-9. PubMed ID: 17693048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse drug reactions in Canada. Hematologic reactions to sterol and sterolin-containing products.
    Can Fam Physician; 2004 Aug; 50():1115-6. PubMed ID: 15455811
    [No Abstract]   [Full Text] [Related]  

  • 32. European biologicals registers: methodology, selected results and perspectives.
    Zink A; Askling J; Dixon WG; Klareskog L; Silman AJ; Symmons DP
    Ann Rheum Dis; 2009 Aug; 68(8):1240-6. PubMed ID: 18647854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety assessment of personal care products/cosmetics and their ingredients.
    Nohynek GJ; Antignac E; Re T; Toutain H
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):239-59. PubMed ID: 20005888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of regulating biotechnology-derived animals in Canada: animal health and food safety considerations.
    Kochhar HP; Evans BR
    Theriogenology; 2007 Jan; 67(1):188-97. PubMed ID: 17097725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmarket surveillance. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(109):38878-92. PubMed ID: 12053947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacologic surveillance and safety evaluation of new drugs].
    Reys LL
    Acta Med Port; 1991; 4(3):141-6. PubMed ID: 1950664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 38. Identifying optimal postmarket surveillance strategies for medical and surgical devices: implications for policy, practice and research.
    Gagliardi AR; Umoquit M; Lehoux P; Ross S; Ducey A; Urbach DR
    BMJ Qual Saf; 2013 Mar; 22(3):210-8. PubMed ID: 23322750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory agencies, pharmaceutical information and the Internet: a European perspective.
    Bauschke R
    Health Policy; 2012 Jan; 104(1):12-8. PubMed ID: 22101089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.